共 50 条
- [21] Significant efficacy demonstrated with the combination of ulixertinib (ERK1/2 inhibitor) and CDK4/6 inhibitors in MAPK altered modelsCANCER RESEARCH, 2022, 82 (12)Emery, Caroline M.Corgiat, BrianDavis, JustinSorrell, DavidJohnson, MitchKreider, BrentKnoerzer, Deborah
- [22] A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumorsNature Cancer, 2023, 4 : 240 - 256Ana Ruiz-SaenzChloe E. AtreyaChangjun WangBo PanCourtney A. DreyerDiede BrunenAnirudh PrahalladDenise P. MuñozDana J. RammsValeria BurghiDanislav S. SpassovEleanor FewingsYeonjoo C. HwangCynthia CowdreyChristina MoeldersCecilia SchwarzerDenise M. WolfByron HannScott R. VandenBergKevan ShokatMark M. MoasserRené BernardsJ. Silvio GutkindLaura J. van ‘t VeerJean-Philippe Coppé
- [23] A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumorsNATURE CANCER, 2023, 4 (02) : 240 - +Ruiz-Saenz, AnaAtreya, Chloe E.Wang, ChangjunPan, BoDreyer, Courtney A.Brunen, DiedePrahallad, AnirudhMunoz, Denise P.Ramms, Dana J.Burghi, ValeriaSpassov, Danislav S.Fewings, EleanorHwang, Yeonjoo C.Cowdrey, CynthiaMoelders, ChristinaSchwarzer, CeciliaWolf, Denise M.Hann, ByronVandenBerg, Scott R.Shokat, KevanMoasser, Mark M.Bernards, ReneGutkind, J. Silviovan 't Veer, Laura J.Coppe, Jean-Philippe
- [24] Combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients: Correlative studies from a phase 2 trialCANCER RESEARCH, 2022, 82 (12)Tian, JunChen, Jonathan H.Chao, Sherry X.Pelka, KarinJorgji, VjolaBaiev, IslamBradford, William B.Wong, EdmondSindurakar, PrincyOka, TomonoriDemehri, ShadmehrHacohen, NirCorcoran, Ryan B.
- [25] Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid CancerTHYROID, 2023, 33 (10) : 1201 - 1214Gunda, ViswanathGhosh, ChandrayeeHu, JiangnanZhang, LisaZhang, Ya qinShen, MinKebebew, Electron
- [26] Combining the HSP90 Inhibitor, AT13387, with Vemurafenib Delays the Emergence of Resistance in a Preclinical Model of BRAFV600E Mutant MelanomaJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 58 - 58Smyth, T.Lewis, J.Thompson, N.Lyons, J.Azab, M.Wallis, N.
- [27] Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational modelNPJ SYSTEMS BIOLOGY AND APPLICATIONS, 2017, 3Kirouac, Daniel C.Schaefer, GabrieleChan, JocelynMerchant, MarkOrr, ChristineHuang, Shih-Min A.Moffat, JohnLiu, LichuanGadkar, KapilRamanujan, Saroja
- [28] Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational modelnpj Systems Biology and Applications, 3Daniel C. KirouacGabriele SchaeferJocelyn ChanMark MerchantChristine OrrShih-Min A. HuangJohn MoffatLichuan LiuKapil GadkarSaroja Ramanujan
- [29] Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal CancerCANCER DISCOVERY, 2018, 8 (04) : 428 - 443Corcoran, Ryan B.Andre, ThierryAtreya, Chloe E.Schellens, Jan H. M.Yoshino, TakayukiBendell, Johanna C.Hollebecque, AntoineMcRee, Autumn J.Siena, SalvatoreMiddleton, GaryMuro, KeiGordon, Michael S.Tabernero, JosepYaeger, RonaO'Dwyer, Peter J.Humblet, YvesDe Vos, FilipJung, A. ScottBrase, Jan C.Jaeger, SavinaBettinger, SeverineMookerjee, BijoyeshRangwala, FatimaVan Cutsem, Eric
- [30] The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasisNEURO-ONCOLOGY, 2024, 26 (05) : 889 - 901de Sauvage, Magali A.Torrini, ConsueloNieblas-Bedolla, EdwinSummers, Elizabeth J.Sullivan, EmilyZhang, Britney S.Batchelor, EmilyMarion, BraxtonYamazawa, ErikaMarkson, Samuel C.Wakimoto, HiroakiNayyar, NaemaBrastianos, Priscilla K.